Actavis - Articles and news items

Shire wins Lialda patent trial against Watson

Industry news / 29 March 2016 / Victoria White

The US District Court for Southern Florida has upheld Shire’s patent for Lialda (mesalamine) delayed release tablets for adults with ulcerative colitis…

European Pharmaceutical Review’s top 10 stories from 2015

Blog / 28 January 2016 / Victoria White, Digital Content Producer, European Pharmaceutical Review

2015 was an interesting year for the pharmaceutical industry. Here we pick a selection of the top stories that hit the headlines…


UK court rules in favour of Lilly in Alimta vitamin regimen patent lawsuit

Industry news / 26 June 2015 / Victoria White

The UK Court of Appeal has ruled in favour of Lilly in the Actavis v. Eli Lilly and Company Alimta vitamin regimen patent lawsuit…

Actavis responds to SMC’s reccommendation of Ozurdex as a valuable treatment option for patients with diabetic macular oedema

Industry news / 13 May 2015 /

Actavis has responded to the decision by the SMC to accept Ozurdex for use by NHS Scotland for the treatment of visual impairment in patients with DMO…


Actavis receives FDA approval of SAPHRIS® for pediatric patients (age 10-17) for acute treatment of manic or mixed episodes of bipolar I disorder

Industry news / 13 March 2015 / Actavis

Actavis plc announced that the U.S. Food and Drug Administration has approved its supplemental new drug application (sNDA) for SAPHRIS® (asenapine) as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients…

Actavis logo

Actavis to acquire Auden Mckenzie for £306m

Industry news / 27 January 2015 / Actavis

Actavis plc and the owners of Auden Mckenzie Holdings Limited, a dynamic and fast growing company focused on the development, licensing and marketing of niche generic medicines and proprietary brands in the UK, announced that they have reached a definitive agreement, under which Actavis will acquire Auden Mckenzie for approximately £306 million in cash…

Pin in map of Germany on Munich

Munich named as top location for biotechnology and pharmaceutical industries

Industry news / 24 November 2014 / BioM Biotech Cluster Development GmbH

Munich is the top location for biotechnology and pharmaceutical industries according to a new study by the Chamber of Industry and Commerce (IHK)…


Actavis continues consolidation March with highly priced allergan deal, says GlobalData director

Industry news / 18 November 2014 / Actavis

Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, says: “Actavis has agreed to purchase Allergan for around $66 billion, in a deal which draws to an end Valeant’s lengthy wrangle to acquire the Botox manufacturer…”

Actavis logo

FDA Advisory Committee recommends against approval of Actavis’ Nebivolol/Valsartan fixed-dose combination NDA for treatment of hypertension

Industry news / 10 September 2014 / Actavis

Actavis plc confirmed that the U.S. Food and Drug Administration’s Cardiovascular and Renal Drugs Advisory Committee has voted to recommend against approval of Actavis’ New Drug Application for the fixed-dose combination of nebivolol and valsartan for the treatment of hypertension…

Actavis logo

Actavis confirms generic Diclegis® Patent challenge

Industry news / 15 July 2014 / Actavis

Actavis plc confirmed that it has filed an Abbreviated New Drug Application with the FDA seeking approval to market Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-release tablets…

Actavis logo

Actavis confirms Generic Ampyra® patent challenge

Industry news / 9 July 2014 / Actavis

Actavis plc confirmed that it has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Dalfampridine Extended-release Tablets, 10 mg…

Actavis logo

Actavis plc appoints new members and announces changes to Board of Directors following close of Forest Laboratories, Inc. acquisition

Industry news / 2 July 2014 / Actavis

Actavis plc announced the appointment of three new members to the Company’s Board of Directors, including Actavis’ newly appointed CEO and President, Brenton L. Saunders…

  • Page 1 of 2
  • 1
  • 2
  • >


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...